Plant Name: Lonicera japonica
Taxonomic Information:
Plant ID: NPO1515
Plant Latin Name: Lonicera japonica
Taxonomy Genus: Lonicera
Taxonomy Family: Caprifoliaceae
Plant External Links:
NCBI TaxonomyDB:
105884
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Thailand; South Korea; China; IndiaTraditional Medicine System:
Indian Folk; TCM; KampoMedicinal Functions:
Antibacterial; Antiinflammatory; Antispasmodic; Antiviral; Depurative; Diuretic; Febrifuge; Skin; TB; VD
Geographical Distribution:
India; South Korea; China; Thailand
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| ADORA2A; ADORA1; FFAR4; ADORA3; FFAR1; | |
| RECQL; ADK; HSD17B10; AKR1B10; ALOX12; HSD17B1; CBR1; AKR1B1; HSD17B2; ALOX15; NOX4; POLB; | |
| ACHE; | |
| MET; AXL; KDR; FLT3; CDK1; PIM1; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA14; CA7; CA4; | |
| AR; NR3C2; PGR; NR3C1; | |
| RORC; | |
| ESR2; | |
| NR1H4; | |
| TYR; XDH; | |
| KDM4E; | |
| MMP12; MMP9; MMP1; MMP2; | |
| AHR; HIF1A; NFKB1; | |
| FUT7; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; SERPINA6; FABP4; THPO; FABP3; APP; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
| Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.550E-11 | 3.375E-08 | AR, ESR2, HSD17B1, NR1H4, NR3C1, NR3C2, PGR, RORC, SERPINA6 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.261E-09 | 1.175E-06 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.295E-09 | 1.175E-06 | AR, ESR2, NR1H4, NR3C1, NR3C2, PGR, RORC |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.015E-08 | 6.312E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.723E-08 | 9.380E-06 | AHR, AR, ESR2, NR1H4, PGR, RORC |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.733E-08 | 1.322E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 8.012E-08 | 3.033E-05 | AR, CDK1, ESR2, NR1H4, NR3C1, NR3C2, PGR, RORC |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.012E-08 | 3.033E-05 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.078E-08 | 3.033E-05 | AHR, CSNK2A1, HIF1A, KDR, NR3C1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 9.066E-08 | 3.346E-05 | AR, CA12, CA2, CA4, CA7, ESR2, MMP1, MMP12, MMP2, MMP9, NR1H4, NR3C1, NR3C2, PGR, RORC |
| MF | Unclassified; | GO:0004872; receptor activity | 1.692E-07 | 5.498E-05 | ADORA1, ADORA2A, ADORA3, AHR, AR, AXL, ESR2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, NR1H4, NR3C1, NR3C2, PGR, RORC, TSHR |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.791E-07 | 8.325E-05 | AKR1B1, ALOX12, AR, CDK1, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MMP12, MMP2, MMP9, PIM1, THPO, TSHR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.219E-07 | 1.209E-04 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.568E-07 | 1.985E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.114E-06 | 2.756E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.382E-06 | 3.168E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.899E-06 | 5.739E-04 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.297E-06 | 6.418E-04 | APP, AR, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, NR3C1, RORC |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.301E-06 | 6.418E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 3.626E-06 | 6.806E-04 | AKR1B1, ALOX12, APP, CA12, CA2, CA7, FABP3, FABP4, FFAR1, HIF1A, MET, NOX4, NPSR1, NR1H4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.395E-06 | 9.399E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.162E-06 | 1.182E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.113E-05 | 1.706E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.113E-05 | 1.706E-03 | ADORA2A, CA2, CA7 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.142E-05 | 1.739E-03 | ACHE, AR, HSD17B1, IGF1R, NR3C1 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.185E-05 | 1.756E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.185E-05 | 1.756E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.209E-05 | 1.779E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.536E-05 | 2.187E-03 | AKR1B1, AR, CA2, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3, NFKB1, NR3C1, TSHR |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 3.336E-05 | 4.402E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 3.548E-05 | 4.465E-03 | AR, PGR |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.548E-05 | 4.465E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.548E-05 | 4.465E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.548E-05 | 4.465E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.548E-05 | 4.465E-03 | ADORA1, ADORA2A |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 3.649E-05 | 4.541E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0010557; positive regulation of macromolecule biosynthetic process | 3.847E-05 | 4.733E-03 | AHR, APP, AR, AURKB, CDK1, ESR2, HIF1A, IGF1R, KDR, MET, MMP12, NFKB1, NOX4, NR1H4, NR3C1, PGR, RORC |
| BP | GO:0008152; metabolic process | GO:0016042; lipid catabolic process | 4.101E-05 | 5.017E-03 | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.508E-05 | 5.334E-03 | ADORA1, CA2, CA4, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0051179; localization | GO:0006909; phagocytosis | 5.570E-05 | 6.417E-03 | ADORA1, ADORA2A, ALOX15, AXL |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 5.716E-05 | 6.516E-03 | ADORA3, APP, AR, CYP1B1, ESR2, NFKB1, NR1H4, PIM1 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 5.945E-05 | 6.708E-03 | AKR1B1, AXL, CDK1, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 6.032E-05 | 6.771E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.205E-05 | 6.894E-03 | ALOX15, APP, FFAR4, KDR, NOX4, THPO |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.722E-05 | 7.318E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.080E-05 | 7.632E-03 | CYP1A1, CYP1A2 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 7.338E-05 | 7.794E-03 | ADORA2A, CYP19A1, FFAR1, HIF1A, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 7.633E-05 | 7.943E-03 | MMP1, MMP12, MMP2, MMP9 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 7.618E-05 | 7.943E-03 | ADORA1, ADORA2A, ADORA3, APP, AXL, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 8.309E-05 | 8.495E-03 | ACHE, ADK, AKR1B1, AKR1B10, CBR1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 8.379E-05 | 8.526E-03 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1 |
| BP | GO:0050896; response to stimulus | GO:0046688; response to copper ion | 8.686E-05 | 8.757E-03 | CDK1, CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.591E-08 | 1.138E-06 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.174E-09 | 3.108E-07 | CA12, CA2, CA4, CA7, CA14 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.969E-08 | 1.892E-06 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.378E-06 | 8.500E-05 | CBR1, ALOX15, ADK, AKR1B1, ALOX12, CYP2C19, TYR, CYP19A1, HSD17B10, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, XDH |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 6.760E-06 | 1.931E-04 | AR, FLT3, MMP1, MMP2, HIF1A, MET, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.103E-06 | 1.931E-04 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.055E-05 | 1.082E-03 | MMP2, KDR, HIF1A, MMP9, MET, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.544E-05 | 1.082E-03 | CBR1, ALOX15, ALOX12, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.052E-04 | 1.428E-03 | CBR1, CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 9.440E-05 | 1.428E-03 | SLCO1B1, CA2, SLCO1B3, NR1H4 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 3.435E-04 | 3.334E-03 | FLT3, MMP9, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.444E-04 | 4.866E-03 | APP, ALOX15, ALOX12, CYP2C19 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.249E-04 | 3.334E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 7.742E-04 | 6.512E-03 | AR, CDK1, PGR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.497E-04 | 3.334E-03 | MMP1, MMP2, MMP9 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.234E-04 | 1.470E-03 | CYP1A2, ALOX15, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 9.239E-04 | 6.953E-03 | FLT3, PIM1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 8.773E-04 | 6.953E-03 | FABP4, ADORA1, TSHR |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.098E-04 | 1.428E-03 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; AR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; |
| NA: NA | HIV infections | NA | AHR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; NR3C1; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; NR3C2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; AR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; ADORA3; NR3C1; MMP9; NR3C2; PGR; MMP2; APP; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; NR3C1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; AR; NR3C2; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; AKR1B1; MMP1; TYR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; ADORA1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; AR; FLT3; CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ADORA2A; NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
| NA: NA | Obstructive airway diseases | NA | SERPINA6; |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2; MMP1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; NR3C1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; NR3C1; SERPINA6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Uterine fibroids | D25 | PGR; |
| C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; AKR1B1; FFAR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; APP; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; CBR1; ADORA1; ADORA2A; NR3C1; SERPINA6; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; APP; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; |
| NA: NA | Geographic retinal atrophy | NA | APP; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADORA1; ADORA2A; ADORA3; AKR1B1; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; APP; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| NA: NA | Male hypogonadism | NA | AR; |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; NR3C1; NR3C2; FFAR1; |
| N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PGR; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; NR3C2; XDH; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; AR; ACHE; ADORA2A; ADK; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | NR3C2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
